Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSCs in CKD
NCT02195323Phase 1Completed
- Sponsor
- Royan Institute
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in chronic kidney disease (CKD), sponsored by Royan Institute. Primary endpoints: Mass formation at 6 months and Serum Creatinine at 1 month. Started Apr 2014; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02195323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195323.